Press Releases from Aleva Neurotherapeutics (4 total)
Aleva Neurotherapeutics Receives CE Mark for its directSTIM™ Deep Brain Stimul …
Lausanne, Switzerland, December 16, 2019 – Aleva Neurotherapeutics, a leading developer of implants for deep brain stimulation (DBS) in major neurological indications such as Parkinson’s disease and essential tremor, today announced that it has been awarded the CE Mark for its flagship product, the directSTIMTM Deep Brain Stimulation System.
Aleva’s revolutionary DBS system incorporates directional electrode technology and is designed to be more precise and efficient, with optimized stimulation that…
Aleva Neurotherapeutics Raises CHF 4.0 Million in Series B Financing Round
- Lead investor Banexi Ventures Partners joins strong investment consortium -
Lausanne, Switzerland, April 10, 2012 – Aleva Neurotherapeutics, a company developing next-generation implants for Deep Brain Stimulation (DBS) in major neurological indications such as Parkinson´s disease or depression, today announced the closing of a Series B financing round totaling CHF 4.0 million.
Banexi Ventures Partners acted as a lead investor in the financing, with selected private investors also participating in…
Aleva Neurotherapeutics Expands Board of Directors
- Entrepreneur Martin Velasco and Industry Expert Scott R. Ward Appointed as Board Members -
Lausanne, Switzerland, March 20, 2012 – Aleva Neurotherapeutics, a company developing next-generation implants for Deep Brain Stimulation (DBS) in major neurological indications such as Parkinson´s disease or depression, today announced the expansion of its Board of Directors. Martin Velasco, a seasoned entrepreneur and business angel, and Scott R. Ward, advisor and former Senior Vice President and…
Aleva Neurotherapeutics Closes EUR 9.5 Million Series A Financing Round
- Novel Products for Deep Brain Stimulation (DBS) to Be Advanced Into the Clinic -
Lausanne, Switzerland, August 25, 2011 – Aleva Neurotherapeutics, a company developing next-generation implants for Deep Brain Stimulation (DBS) in major neurological indications such as Parkinson´s disease or depression, today announced the closing of a Series A financing round totaling EUR 9.5 million. Aleva was founded in 2008 as a spin-off from the Ecole Polytechnique Fédérale de…
